Solstice Raises $21M Series A

Solstice, a New York City-based company offering an AI-native marketing platform for the pharmaceutical and life sciences industries, has raised $21 million in Series A, bringing its total backing to approximately $25 million.

Investors

The round was led by Transformation Capital, a growth equity venture firm focused on digital health. Additional participants included the company’s existing seed investors, Twelve Below and Virtue Ventures, along with multiple strategic angel investors.

Solstice Use of Funds

Solstice plans to use the capital to support go-to-market expansion, accelerate product engineering, and significantly grow its internal product and customer success teams.

About Solstice

Founded in 2023 by Li Yiwen and Aris Saxena, Solstice is a software company that provides an AI-native platform to streamline the pharmaceutical marketing review process. Its software helps biopharma brands automate medical, legal, and regulatory (MLR) reviews, enabling them to condense content approval timelines from months to 10 days or less while ensuring clinical grounding and compliance.

Funding Details

Company Website: https://www.solsticehealth.co/

Company: Solstice
Raised: $21M
Round: Series A
Funding Date: May 28, 2026
Lead Investor: Transformation Capital
Additional Investors: Twelve Below, Virtue Ventures, strategic angel investors
Company Website: https://www.solsticehealth.co/
Software Category: Digital Health / Pharma Tech
Source: https://ventureburn.com/solstice-secures-21m-series-a-for-pharma-innovation/?amp=1